Incidental venous thromboembolism detected by PET-CT in patients with cancer: Prevalence and impact on survival rate

Callejas, Matías; Errázuriz, Juan Ignacio; Castillo, F.; Otarola, Claudia; Riquelme, Carlos; Ortega, Claudia; Huete, Álvaro; Bächler, Pablo

doi:10.1016/j.thromres.2014.02.005

Cited by 13 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several retrospective studies in patients with cancer indicate that incidental PE can have important effects on survival, as well as on recurrent VTE [50,[59][60][61][62][63][64][65]. In one study that included a control group of patients without PE, matched for age, cancer histology and severity, the median survival in patients with incidental PE was 8 months, compared to 12 months for the matched controls [50].…”

Section: Relevance Of Incidental Pementioning

confidence: 99%

Management of incidental pulmonary embolism

Klok

Huisman

2017

Eur Respir J

View full text Add to dashboard Cite

Incidental pulmonary embolism (PE) is a frequent finding on routine computed tomography (CT) scans of the chest, occurring in 1.1% of coronary CT scans and 3.6% of oncological CT scans. Despite this high frequency, optimal management of incidental PE has not been addressed in clinical trials and remains the subject of debate. Although these CT scans have not been performed with a dedicated PE protocol and have suboptimal contrast enhancement, diagnosis of incidental PE has been shown to be accurate up to the segmental and subsegmental arteries. The embolic load in incidental PE is lower than that in symptomatic PE. Even so, observational studies suggest that the natural course of incidental PE is similar to that of symptomatic PE with regard to the risk of recurrent venous thrombotic disease and mortality. Interestingly, the increased use of more advanced CT technology has coincided with an increase in the rate of incidental subsegmental PE, as is the case for symptomatic subsegmental PE. Although clinical trials are lacking, and observational data are limited to cancer-associated incidental PE, the consensus is that the management of incidental PE is identical to that of symptomatic PE, including the choice of optimal drug class, outpatient treatment and total duration of treatment.

show abstract

Section: Relevance Of Incidental Pementioning

confidence: 99%

Management of incidental pulmonary embolism

Klok

Huisman

2017

Eur Respir J

View full text Add to dashboard Cite

show abstract

Section: Reviewmentioning

confidence: 99%

“…Calleias et al [ 22 ] have evaluated the prevalence of incidental VTE detected by PET-CT among cancer patients in a retrospective study. The prevalence of incidental VTE detected by PET-CT was 1.4 % [ 22 ]. Patients with genitourinary malignancies, colorectal cancer and lung cancer had the highest rates of incidental VTE at PET-CT [ 22 ].…”

Section: Reviewmentioning

confidence: 99%

Venous thromboembolism and lung cancer: a review

Vitale

D’Amato

Calabrò

et al. 2015

Multidiscip Respir Med

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, advanced disease, pneumonectomy, chemotherapy including antiangiogenic therapy. Other risk factors are pretreatment platelet counts and increased release of TF-positive microparticles. Elevated D-dimer levels do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in lung cancer patients. Mechanisms responsible for the increase in venous thrombosis in patients with lung cancer are not understood.Currently no biomarker is recognized as a predictor for VTE in lung cancer patients.Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with lung cancer who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at an increased risk of developing a thromboembolism.

show abstract

“…The prevalence of incidental VTE detected by PET-CT was 1.4%. [17] Patients with genitourinary malignancies, lung cancer and colorectal cancer had the highest rates of incidental VTE at PET-CT. [17] In a retrospectively review of colorectal cancer patients after surgery Kim et al [18] reported that the incidence of VTE was approximately 3% within 1 year.…”

Section: World Journal Of Pharmaceutical Researchmentioning

confidence: 97%

“…Almost all of these unexpected VTE cases were significantly associated with a diagnosis of metastatic-stage cancer. [16] In a retrospective study of 1331 consecutive adult patients, Callejas et al [17] have evaluated the prevalence of incidental VTE detected by PET-CT among cancer patients. The prevalence of incidental VTE detected by PET-CT was 1.4%.…”

Section: World Journal Of Pharmaceutical Researchmentioning

confidence: 99%

Venous Thromboembolism and Colorectal Cancer: A Review

Ding¹

2017

WJPR

View full text Add to dashboard Cite

Venous thromboembolism is a common complication of malignancies and epidemiological studies suggested that colorectal cancer belong to the group of malignancies with the highest incidence rates of VTE.Risk factor for VTE in colorectal cancer patients are advanced disease, colorectal surgery and chemotherapy including anti-angiogenic therapy.Other risk factors are pretreatment platelet counts and increased release of TF-positive micro-particles. Elevated D-dimer level do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in colorectal cancer patients.Mechanisms responsible for the increase in venous thrombosis in patients with colorectal cancer are not understood. Currently no biomarker is recognized as a predictor for VTE in colorectal cancer.Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with colorectal cancer who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at an increased risk of developing a thromboembolism.

show abstract

Incidental venous thromboembolism detected by PET-CT in patients with cancer: Prevalence and impact on survival rate

Cited by 13 publications

References 30 publications

Management of incidental pulmonary embolism

Management of incidental pulmonary embolism

Venous thromboembolism and lung cancer: a review

Venous Thromboembolism and Colorectal Cancer: A Review

Contact Info

Product

Resources

About